Literature DB >> 30607320

lncRNA-based study of epigenetic regulations in diabetic peripheral neuropathy.

Muhamad Fachrul1, Didik H Utomo2,3, Arli A Parikesit1.   

Abstract

Diabetes remains one of the most prevalent non-communicable diseases in the world, affecting over 400 million of people worldwide, causing serious complications leading to amputations and even death. Over the years, researchers have found that, in addition to genomic mutations, epigenetic mechanisms also play a role in the development of diabetes-specifically type-2 diabetes. Long noncoding RNAs (lncRNAs) have been linked to mediate epigenetic mechanisms, including those in late-stage diabetes. This study attempts to assess the unexplored topic of how lncRNAs could be used to assess the epigenetic mechanisms present in diabetic peripheral neuropathy (DPN); a serious complication of the disease often leading to amputation. Differential lncRNA expression analysis was done with a dataset containing DPN and healthy patients. Standard and corrected t test, and also LIMMA was applied. Results of this study indicates the usefulness of lncRNAs as an exploratory tool to elucidate the complexity of the epigenetic mechanisms of human DPN.

Entities:  

Keywords:  Epigenetic; In Silico; Type-2 diabetes; lncRNA

Year:  2018        PMID: 30607320      PMCID: PMC6314784          DOI: 10.1007/s40203-018-0042-8

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  2 in total

1.  Deregulated Expression of Long Non-coding RNA HOX Transcript Antisense RNA (HOTAIR) in Egyptian Patients with Multiple Myeloma.

Authors:  Amira Mohamed Foad Shehata; Samar M Kamal Eldin; Nahla F Osman; Mohamed A Helwa
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-16       Impact factor: 0.900

2.  Long Non‑Coding RNAs Regulate Inflammation in Diabetic Peripheral Neuropathy by Acting as ceRNAs Targeting miR-146a-5p.

Authors:  Yonghao Feng; Ying Ge; Men Wu; Yangmei Xie; Ming Wang; Yinghui Chen; Xiaohong Shi
Journal:  Diabetes Metab Syndr Obes       Date:  2020-02-18       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.